OHAMR Call for proposals 2026

General Information

• Type: Partner looking for project
• Organisation: LyseNTech
• Country: South Korea (KR)
• Career stage: Other.

Research area

• Scientific area(s) of the call:
  1. Topic 1: Identify and develop new combination treatments using existing or innovative antimicrobials or antimicrobial with adjunctive treatments to extend drug efficacy and combat resistance.
• One Health Setting:

  H - Human Health

  A - Animal Health

• Keywords:

  Engineered endolysin; Gram-negative; combination with SoC antibiotics; phase 1 IND approved

• Brief description of your expertise / expertise you are looking for:

  LyseNTech (www.lysentech.com) is a startup in Korea. It does not meet the eligibility of participating countries for funding in this call. But it has two very promising assets. 1) It has an engineered endolysin pipeline targeting broad spectrum Gram negatives. The IND for phase 1 clinical trial was approved for the endolysin in Korea. During the preclinical development, synergistic or additive effects with SoC antibiotics were confirmed in vitro and in vivo. 2) It also has a library of bacteriophages in the Bacteriophage Bank of Korea (www.phagebank.or.kr). It stocks 3,500 phages targeting major pathogens. Phage-antibiotic synergy has been well documented. It is our intention to provide the endolysin and/or phages for a consortium in this call and prove the competitiveness of our assets. It would be best if a consortium can find a way to fund us, or purchase the endolysin and/or phages as materials for use in the project (no licensing involved).

• Brief description of your project / the project you would like to join:

  Based on proven synergy/additive effects of the endolysin/phages with SoC antibiotics, we would like to join a consortium for Topic 1 involving human and/or animals.

Heejoon Myung

• Organisation: LyseNTech
• Position: CEO
• E-mail: hjmyung@lysentech.com
• Phone: +82-31-330-4098
• Web: www.lysentech.com